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http://dx.doi.org/10.1016/j.jmii.2012Aeromonas species, aquatic Gram-negative bacilli, distributed globally and ubiquitously in the
natural environment, may be implicated in a variety of human diseases. They can produce
various b-lactamases which confer resistance to a broad spectrum of b-lactams, and therefore
in vitro susceptibility testing must be used to guide antimicrobial therapy. However, conven-
tional in vitro susceptibility tests may sometimes fail to detect these b-lactamases, and hence
raise a therapeutic challenge. In this review article, two chromosomally mediated b-lacta-
mases (i.e., AmpC b-lactamases and metallo-b-lactamases) and acquired extended-spectrum
b-lactamases in aeromonads are reviewed, and the clinical implications of the complexity of
b-lactamases are discussed.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Aeromonas species, an aquatic Gram-negative bacilli, is
distributed globally and grows ubiquitously in the natural
environment. The role of aeromonads as human pathogenstitute of Infectious Diseases
arch Institutes, Number 367,
OC.
inet.net (C.-J. Wu).
an Society of Microbiology. Publ
.08.008in natural disasters was reinforced by the observation that
they ranked as the single most common pathogen identified
in tsunami survivors with skin or soft tissue infections in
Thailand in 2004.1 Besides skin or soft tissue infections,
aeromonads can cause a variety of human diseases in the
community or hospital settings, such as gastroenteritis,
septicemia, abdominal/peritoneal sepsis, hepatobiliary
tract infections, and catheter-related infections.2,3 Both
immunocompromised and immunocompetent individuals
would acquire infections due to aeromonads, mostly from
oral consumption of or direct mucocutaneous contact withished by Elsevier Taiwan LLC. All rights reserved.
b-Lactamases in Aeromonas species 399contaminated water or foods.2 A. hydrophila, A. caviae,
and A. veronii bv. sobria are the three principal Aeromonas
species found to be associated with human diseases.2
Aeromonads can produce various b-lactamases which
confer resistance to a broad spectrum of b-lactams, and
therefore in vitro susceptibility testing must be used to
guide antimicrobial therapy.4 Three major classes of chro-
mosomally mediated b-lactamasesdAmbler class B, C, and
D b-lactamasesdhave been recognized in Aeromonas
species.2,5 Metallo-b-lactamases (MBLs), AmpC b-lacta-
mases, and penicillinases are the principal class B, C, and D
b-lactamases harbored in aeromonads, respectively.2
Another important class of b-lactamases addressed is
class A extended-spectrum b-lactamases (ESBLs), which
have been increasingly reported in both clinical and envi-
ronmental aeromonads.6,7 However, conventional in vitro
susceptibility tests would sometimes fail to detect these
b-lactamases,6,8,9 and hence pose a therapeutic challenge.
An understanding of the types of b-lactamases harbored in
clinically relevant Aeromonas species is important, and
would be a guide for antimicrobial therapy. In this article,
the drug susceptibility profiles of major b-lactamases found
in Aeromonas species and clinical implications of the
complexity of b-lactamases are discussed.General susceptibility profiles
Much of the susceptibility information on aeromonads is
based solely upon the most clinically relevant Aeromonas
species, i.e., A. hydrophila, A. caviae, and A. veronii bv.
sobria.2 It is not clear whether those profiles can be
extrapolated to other less frequently encountered taxa
causing illness.2 Currently, consensus guidelines for the
antimicrobial susceptibility testing of Aeromonas spp.,
including the members of A. hydrophila complex, A. caviae
complex, and A. veronii complex, have been published by
the Clinical and Laboratory Standards Institute (CLSI),
providing information and interpretative criteria for brothTable 1 Summary of in vitro drug susceptibilities of clinical iso
conducted by Janda et al,12 Wu et al,3 and Lamy et al11
Drugs
A. hyd
Ampicillin or amoxicillin 0/0/0
Ampicillin/sulbactam or Amoxicillin/clavulanate 75/0/1
Piperacillin d/38/
Piperacillin/tazobactam d/90/
Cephalothin 21/5/1
Cefuroxime 92/90/
Cefotaxime or ceftriaxone 92/90/
Cefepime d/98/
Aztreonam d/98/
Imipenem d/73/
Gentamicin d/92/
Amikacin d/95/
Ciprofloxacin 100/85
Co-trimoxazole 100/22
d Z data not available.microdilution and disk diffusion testing.10 Of the threemajor
Aeromonas species, some species-specific susceptibility
variations have been found, as demonstrated by the
summary of three previous reports (Table 1),3,11,12 in which
the methods of susceptibility testing and interpretative
criteria varied with studies. Generally, carbapenem
resistance was occasionally found in A. hydrophila
and A. veronii isolates, while A. caviae isolates were
carbapenem-susceptible. A. hydrophila and A. caviae
isolates were cephalothin-resistant and more frequently
displayed resistance to cefuroxime, ceftriaxone, or cefo-
taxime than did A. veronii isolates, which were cephalothin-
susceptible. Most of the A. hydrophila, A. caviae, and
A. veronii isolates displayed resistance to ampicillin and
amoxicillin. Of interest, A. enteropelogenes (formerly
A. tructi or A. trota) is always susceptible to ampicillin and is
the only known Aeromonas species that produces only one b-
lactamasedmolecular class C b-lactamase.13 In a study by
Fosse et al,5 a series of 417 wild-type Aeromonas strains,
biochemical identification, and susceptibility testing with 11
b-lactams by the disk-diffusion method revealed five
predominant phenotypes: A. hydrophila complex/class B, C,
and D b-lactamases; A. caviae complex/class C and D b-lac-
tamases; A. veronii complex/class B and D b-lactamases;
A. schubertii spp./class D b-lactamase; A. trota spp./class C
b-lactamase. These observations are in agreement with
previous observations and suggest that the distribution of
three chromosomally mediated class B, C, and D b-lacta-
mases among aeromonads is species-specific, which could be
a useful scheme for taxonomic differentiation and a guide of
antimicrobial therapy. Although susceptibility variations
between species have been found in selected studies, these
results should be considered preliminary at present. For
examples, many A. veronii bv. sobria isolates were
hybridized-positive for a class C cephalosporinase gene,
cepS.14 However,A. veronii bv. sobria 163a, the strain in that
CepS cephalosporinase that was originally identified, is
actually a strain of A. hydrophila, with a 100% identity to
the 16S rRNA and rpoB sequences of A. hydrophila ATCC7966lates of three common Aeromonas species from three studies
% of susceptible isolates in studies by Janda/Wu/Lamy
rophila A. caviae A. veronii bv. sobria
13/0/6.7 9/7/3.7
5.4 80/0/40 100/7/11.1
88.4 d/59/100 d/82/100
88.4 d/89/100 d/92/100
1.5 13/0/20 82/93/100
d 72/74/d 100/100/d
92.3 93/74/100 100/100/100
100 d/96/100 d/100/96.3
d d/89/d d/100/d
84.6 d/96/93.3 d/64/37
100 d/93/100 d/96/100
100 d/100/100 d/100/96.3
/84.6 100/85/93.3 100/89/100
/80.8 100/15/80 100/64/100
400 P.-L. Chen et al.type strain.15 Therefore, in the modern era of taxonomy
based on molecular identification, the knowledge of the
distribution of chromosomally mediated b-lactamases
among different Aeromonas genomospecies should be
reevaluated. The b-lactamases intrinsically carried by Aer-
omonas species based on current knowledge are summarized
in the Table 2, and the MBLs and AmpC b-lactamases are
discussed in detail in the following sections.
Metallo-b-lactamases
The most commonly mentioned MBL in Aeromonas species
is CphA, which has a very specific substrate profile, being
active on penems and carbapenems only, but not on peni-
cillins and cephalosporins.16 Other MBLs among aeromonads
were identified, including ImiS,17 IMP-19,18 and VIM.19 The
distribution of cphA among aeromonads is species-specific,
mainly found in A. hydrophila, A. veronii, and A. jandaei,
but not in A. caviae.20,21 We further noticed that the
isolates of A. aquariorum, a recently described species that
was initially isolated from ornamental fish aquaria in
2008,22 also carried cphA.8 A. aquariorum has been asso-
ciated with a wide spectrum of human diseases, such as
septicemia, skin soft tissue infections, and gastroenter-
itis,23 and was widely distributed in clinical and environ-
mental specimens.24,25 A. aquariorum and A. hydrophila
subsp. dhakensis are closely related species based on
a phylogenetic analysis of the gyrB, rpoD, and rpoB
genes,26,27 and an identical phenotypic profile of the
inability to produce acid from L-arabinose.28 Till now, the
biological and clinical characteristics of A. aquariorum
have not been well studied, and further studies are
warranted.
The CphA MBL production is not easily detected by
conventional in vitro susceptibility tests with EDTA-based
combination disk diffusion, E-test, or agar dilution
methods with standard inocula, unless large inocula is
adopted.8,9 In a study testing 34 cphA-carrying Aeromonas
blood isolates, all but one (33, 97%) isolates were suscep-
tible to imipenem tested by the disk diffusion, E-test, and
agar dilution (104 CFU spot inocula) with standard inocula,
while 33 (97%) isolates had imipenem MICs of 16 mg/ml,
higher than the susceptible breakpoint (4 mg/ml), by the
agar dilution test using large inocula (107 CFU).
This inoculum effect on imipenem MIC was not observed in
aeromonads without cphA.8 The modified Hodge test
(MHT), recommended for the detection of carbapenemasesTable 2 Species-specific distribution of three chromosome-me
tamase (ESBL) producing isolates among different Aeromonas spe
Ch
Class B
MBL
A. hydrophila þ
A. caviae 
A. veronii bv. sobria þ
A. enteropelogene (formerly A. trota) 
þ Z present; e Z absent; þ/e Z isolates with and without indicatin Enterobacteriaceae by the CLSI,29 is another method to
detect CphA carbapenemases, since 97% of cphA-carrying
Aeromonas blood isolates were MHT-positive.8
The clinical relevance of CphA MBL in Aeromonas species
remained obscure. Theoretically, carbapenem mono-
therapy would fail to inhibit MBL-producing aeromonads in
infectious diseases with high bacterial burdens, such as
peritonitis/abdominal sepsis or necrotizing fasciitis. More-
over, the production of CphA would increase in the pres-
ence of a b-lactamase inducer, such as benzylpenicillin or
imipenem.16 The emergence of imipenem-resistant Aero-
monas isolates during carbapenem treatment or ante-
cedent amoxicillineclavulanate treatment were
reported.8,30,31 These observations highlight the contro-
versy of carbapenem therapy for infectious diseases caused
by cphA-carrying Aeromonas isolates. Therefore, it is
advisable to perform the susceptibility test with a large
inoculum or the MHT before considering a carbapenem-
based chemotherapy for Aeromonas infections.8,9AmpC b-lactamases
In general, AmpC b-lactamases can hydrolyze many
b-lactam antibiotics, including cephamycins and third-
generation cephalosporins, and are resistant to b-lacta-
mase inhibitors, such as clavulanic acid, tazobactam, and
sulbactam.32 However, fourth-generation cephalosporins
are not recognized by AmpC b-lactamases. Aeromonas
AmpC b-lactamases ever reported included CepS from A.
veronii bv. sobria 163a (later reported to be A. hydrophila
strain),15,33 AsbA1 from A. jandaei,34 CepH from A. hydro-
phila,35 CAV-1 from A. caviae,36 MOX-4 from A. caviae,37
and recently described TRU-1 from A. enteropelogene.13
These accumulated findings are in accordance with
Fosse’s observation that AmpC b-lactamases were distrib-
uted among A. hydrophila, A. caviae, and A. enter-
opelogene isolates.
As other bacteria carrying AmpC genes, aeromonads
with AmpC genes do not always express AmpC b-lactamases
and may display cefotaxime susceptibility. The mechanisms
involved in the expression of AmpC b-lactamases include
inducible b-lactamase production in the presence of suit-
able inducers (cefoxitin or imipenem)33 or development of
depressed mutation which leads to a constitutive high-level
production of b-lactamases.14 The frequency of in vitro
production of resistant mutants in Aeromonas isolates wasdiated b-lactamases and reported extended-spectrum b-lac-
cies
romosomally mediated Acquired
Class C
AmpC
Class D
penicillinase
Class A
ESBL
þ þ Ever reported
þ þ Ever reported
þ/ þ Ever reported
þ  Not reported
ed b-lactamase were reported.
b-Lactamases in Aeromonas species 401about 107 to 109, suggesting that a point mutation was
responsible for the generation of mutants.14
The production of AmpC b-lactamase mediating resis-
tance to third-generation cephalosporin poses a therapeutic
challenge in managing Aeromonas infections. For example,
the use of cefoperazone in a patient with A. caviae in the
respiratory tract selected a mutant that constitutively
produced b-lactamase.38 Reported was the emergence of
a cefotaxime-resistant mutant from a wild A. hydrophila
strain under cefotaxime treatment in a burn patient.39 The
observations highlighted the concern of monotherapy with
a third-generation cephalosporin for infections due to AmpC
gene-carrying aeromonads. Currently, there is no ready-to-
use method recommended by the CLSI for screening AmpC
b-lactamases. Therefore, it is prudent to consider A.
hydrophila, A. caviae, and A. enteropelogene isolates as
AmpC gene-carrying species, and monotherapy with cepha-
losporins other than fourth-generation cephalosporins for
invasive infections due to the above Aeromonas species
should be undertaken with caution.Extended-spectrum b-lactamases
ESBLs, belonging to the class A b-lactamases according to
Ambler’s classification, confer resistance to all penicillins,
cephalosporins, and monobactams, but not to cephamycins
or carbapenems, and are inactivated by b-lactamase
inhibitors.40 ESBL-producing aeromonads have been
increasingly reported in recent years. Clinical cases
included a pediatric patient with A. hydrophila sepsis in
2005,41 two isolates with blaTEM-24 gene from diarrheal
feces and wound in 2003 and 2004, respectively,42,43 and an
aged patient with pneumonia caused by A. caviae with
blaCTx-3 gene in 2010.
37 Environmental ESBL-producing
isolates included several isolates with blaPER-1, blaPER-6,
blaSHV-12, blaVEB-1a, blaTLA-2, or blaGES-7 from the Seine
River,7 and the isolates form an urban river in China.44 In
one study investigating 156 Aeromonas blood isolates in
southern Taiwan, four (2.6%) exhibited the ESBL pheno-
type, and two A. caviae isolates possessed blaPER-3 gene
located in both chromosomes and plasmids.6 Unlike chro-
mosomally encoded MBL and AmpC b-lactamases, the
acquisition of ESBL genes in aeromonads may result from
horizontal gene transfer by mobile genetic elements
between aeromonads and coexistent bacteria in aquatic
microenvironments.6
To screen for ESBL production among Aeromonas
isolates, nonsusceptibility of third-generation cephalospo-
rins is probably the laboratory clue. Previous studies
adopted the clavulanate-based synergy test as the ESBL
phenotype among aeromonads,41,43 as those recommended
for phenotypic confirmation of ESBL-producing Enter-
obacteriaceae by CLSI.29 However, the ESBL phenotype may
be difficult to detect using third-generation cephalosporins
as ESBL substrates among AmpC-b-lactamase-producing
bacteria.45 It is possible that antagonism by clavulanate on
ESBL producers may be masked by the coexistence of AmpC
b-lactamases in A. hydrophila and A. caviae strains.
Therefore, cefepime-based tests, such as cefepimeecla-
vulanate combination disk and cefepimeeclavulanate ESBLE-test are suggested for the screening of ESBL-producing
among aeromonads.6
Prior administration of antibiotics is a well-known risk
factor for infections caused by other community-onset
ESBL-producing Enterobacteriaceae bacteremia and
urinary tract infections.46e48 However, the association of
prior exposure of antibiotics with development of ESBL-
producing Aeromonas infections not evident in the
previous study.6 The optimal therapy for ESBL-producing
Aeromonas infections also remains undefined due to the
rarity of clinical reports.6 With initial non-carbapenem
antimicrobial therapy for two patients with pneumonia
and one with necrotizing fasciitis failed,37,41,43 whereas was
effective for three with bacteremia.6 The differences in the
severity of illness at the time of antibiotic initiation and in
the toxin expression from aeromonads and bacterial loads
might have contributed to the different outcomes in these
cases. Theoretically carbapenems, not hydrolyzed by
ESBLs, would work better than penicillins or cephalosporins
against ESBL producers. However, antibacterial activity of
carbapenems may be hampered by CphA MBL in A. hydro-
phila, A. veronii, and A. jandaei isolates.
Induction potential or the selection of resistant mutants
among AmpC-carrying bacteria does not necessarily corre-
late with clinical risk, because a rapid bactericidal action
will kill the organisms before a sufficient quantity of
enzymes has been induced.49 However, it would be
a concern in infected patients with a heavy load of aero-
monads in subinhibitory antibiotic concentrations due to
ischemic microenvironment. Such clinical settings as
necrotizing fasciitis, burn wounds, or abscesses formation,
would favor the emergence of resistant mutants.39 In
infections with high inocula, clinical use of b-lactams,
which are hydrolyzed by AmpC b-lactamases or MBLs,
should be pursued with caution. Therefore, according to
Fosse’s scheme based on the distribution of b-lactamases,
treatment failure is possible in severe infections due to
A. hydrophila with third-generation cephalosporins or car-
bapenem monotherapy, or those due to A. caviae with
third-generation cephalosporin monotherapy, or those due
to A. veronii with carbapenem monotherapy. For severe
infection due to AmpC b-lactamase- and MBL-carrying
aeromonads, fourth-generation cephalosporin would be an
effective b-lactam agent. However, if the causative isolates
turn out to be EBSL producers, the drug of choice will be
limited. In summary, given the current susceptibility data,
the induction potential of multiple intrinsic b-lactamases
and the possibility of the acquisition of ESBL genes,
empirical therapy for severe Aeromonas infections would
consist of a broad-spectrum cephalosporin in combination
with gentamicin or amikacin,11 or one of the fluo-
roquinolones to avoid the complexity of b-lactamase
production. Later, definite therapy can be adjusted
according to the susceptibility profile and accurate species
identification. More susceptibility tests, such as cefepi-
meeclavulanate synergy tests and the MHT, should be
performed in selected Aeromonas isolates and clinical
conditions.6,8
Species-specific distribution of chromosomally mediated
AmpC b-lactamases and MBL, and the acquisition of ESBL
among aeromonads raise the therapeutic concern of broad-
spectrum cephalosporins as monotherapy for severe
402 P.-L. Chen et al.Aeromonas infections. Due to limited data, the optimal
antibiotic for such infections is not conclusive. Moreover,
recent advances in Aeromonas taxonomy have led to the
reclassification of aeromonads with the emergence of new
species. More clinical studies to reveal intrinsic b-lacta-
mase profile and therapeutic outcome in the cases of
infections due to recently recognized Aeromonas genomo-
species are needed.
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